Geron announces updated NCCN guidelines recommending Rytelo

Geron announced that the National Comprehensive Cancer Network, or NCCN, has updated its Clinical Practice Guidelines in Oncology, or NCCN Guidelines, for the treatment of Myelodysplastic Syndromes, or MDS, to recommend Rytelo as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS. Treatments are classified as Category 1 and 2A when there is uniform NCCN consensus of 85% that the intervention is appropriate. The MDS NCCN Guidelines categorize lower-risk MDS patients without the del abnormality and with symptomatic anemia on the basis of ring sideroblasts percentage and serum EPO levels, without specifying red blood cell transfusion burden. For RS- lower-risk MDS patients with symptomatic anemia, Rytelo is recommended as a Category 1 second-line treatment after either erythropoiesis-stimulating agents or luspatercept in patients with serum EPO 500 mU/mL, and as a Category 2A first-line treatment in patients with serum EPO greater than500 mU/mL and unlikely to respond to immunosuppressive therapy. For RS+ lower-risk MDS patients with symptomatic anemia, Rytelo is recommended as a Category 1 second-line treatment after luspatercept in patients with serum EPO =500 mU/mL, and as a Category 2A first-line treatment in patients with serum EPO greater than 500 mU/mL.